business

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

CNBC · May 31, 2026, 12:00 PM · Also reported by 4 other sources

An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.

Read full story on CNBC → More top stories

Also covered by

Investing.com J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study ARY News Erleada: Prostate cancer drug reduces risk of spread and death Investing.com J&J’s apalutamide cuts prostate cancer death risk by 20% Investing.com TiumBio reports trial data for head and neck cancer drug

Aggregated and edited by the Scoop newsroom. We surface news from CNBC alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

Also covered by

More in business